Canadian Aviation Regulations

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Retrieved on: 
星期四, 五月 9, 2024
Cell, Cash, Research, Doctor of Philosophy, AML, Canadian Aviation Regulations, Partnership, Science, Hepatocellular carcinoma, Logic, Patient, Machine learning, Society, Gene, Synthetic biology, Laboratory, Medicine, Acute myeloid leukemia, Annual general meeting, Therapy, SNTI, SAN, Biotechnology, NK, HCC, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported operational updates and financial results for the first quarter of 2024.

Key Points: 
  • The Company is on track to initiate patient dosing in the second quarter of 2024, with initial efficacy data anticipated by year-end 2024, and initial durability data in 2025.
  • Celest plans to enroll patients initially through a pilot trial in mainland China and expects to dose the first patient in the second quarter of 2024.
  • Cash and Cash Equivalents: As of March 31, 2024, Senti Bio held cash and cash equivalents of $23.7 million.
  • Net Loss: Net loss was $12.1 million, or $0.26 per basic and diluted share, for the quarter ended March 31, 2024.

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
星期四, 五月 9, 2024
CD33, Cancer, Gene expression, Cell, Cranial cavity, Myelodysplastic syndrome, DRI, EHA, Survival, Temozolomide, Research and development, Canadian Aviation Regulations, GBM, AML, Leukemia, IND, ASCO, CD123, Patient, Gene, CML, Society, Acute myeloid leukemia, AACR, Annual general meeting, MDS, Acute leukemia, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.
  • “We continued to make significant progress advancing our gamma-delta T cell programs in the first quarter of 2024,” said William Ho, CEO and co-founder of IN8bio.
  • INB-100: Report updated interim results from the ongoing Phase 1 investigator-sponsored trial at the 2024 EHA Annual Meeting, held June 13-16 in Madrid, Spain.
  • INB-200: Report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024 including at the 2024 ASCO Annual Meeting.

Strengthening CAR-T Therapy to Work Against Solid Tumors

Retrieved on: 
星期三, 五月 8, 2024
Immunotherapy, Brain, University, Blood, Prostate, Protein, Mouse, Pancreas, Ovary, Safety, Public health, See, Cancer research, Glioblastoma, Genetic engineering, Invention, TMIGD2, Canadian Aviation Regulations, Urology, National Cancer Institute, Research, Leukemia, Chimera, Lymphoma, CD276, Liver, Microbiology, Medicine, Bone marrow, Neoplasm, Lung, Paper, Antigen, Zang, Immune system, Albert Einstein, Vaccine

"CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.

Key Points: 
  • "CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
  • "We found that our changes to standard CAR-T cell therapy can significantly boost its effectiveness against solid tumors, including often-fatal pancreatic cancer and glioblastomas."
  • Dr. Zang and his colleagues created five CAR-T therapies that they tested on mice implanted with several types of solid human tumors.
  • He later realized that incorporating TMIGD2 into CAR-T cells might enable them to overcome the challenges posed by solid tumors.

Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Retrieved on: 
星期二, 五月 7, 2024
CRISPR, Safety, CREATE, Gene editing, Vivo, MD, RNA, Canadian Aviation Regulations, Cell, Trial of the century, Primate, DNA, Patient, Gene, Society, Antigen, Messenger, Drug development, Annual general meeting, Therapy, Vaccine

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced multiple poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. 

Key Points: 
  • "The data presented at ASGCT showcase that Myeloid continues to lead the field of in vivo immune cell engineering and RNA-enabled gene editing and delivery.
  • The data presented today underlies our in vivo mRNA CAR, MT-302, that continues to progress well in the ongoing clinical study.
  • We are expanding plans for MT-302's clinical use, given several inherent product advantages for patients," said Daniel Getts, Ph.D., Chief Executive Officer of Myeloid.
  • Poster presentation details and abstract highlights include:
    Myeloid has designed novel CARs that achieve expression and function in targeted immune cell populations.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on: 
星期二, 四月 9, 2024
Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points: 
  • The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
  • IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
  • Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
  • “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期一, 四月 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
星期四, 三月 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy

Retrieved on: 
星期一, 三月 18, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, HCC, Canadian Aviation Regulations, Patient, GPC3, City, Cancer, Glypican 3, ARTEMIS, Clinical trial, Therapy, Safety, Liver cancer, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
  • The ARYA-3 trial is evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The ARYA-3 trial has successfully completed Phase I and is now enrolling patients in Phase II.
  • Moving to Phase II marks a significant milestone in our mission to advance cutting-edge therapies for cancer treatment,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
星期四, 四月 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
星期四, 三月 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.